NO962348L - C5a receptor antagonists without agonist activity - Google Patents

C5a receptor antagonists without agonist activity

Info

Publication number
NO962348L
NO962348L NO962348A NO962348A NO962348L NO 962348 L NO962348 L NO 962348L NO 962348 A NO962348 A NO 962348A NO 962348 A NO962348 A NO 962348A NO 962348 L NO962348 L NO 962348L
Authority
NO
Norway
Prior art keywords
analogs
derivatives
receptor antagonists
human
activity
Prior art date
Application number
NO962348A
Other languages
Norwegian (no)
Other versions
NO962348D0 (en
Inventor
Jan Van Oostrum
William C Boyar
Nicholas G Galakatos
Jane V Peppard
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO962348D0 publication Critical patent/NO962348D0/en
Publication of NO962348L publication Critical patent/NO962348L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)

Abstract

Polypeptidanaloger av human C5a som er C5a reseptorantagonister som utviser vesentlig ingen analfylatoksin eller agonistisk aktivitet, og derivater av analogene, og dimeriske former av analogene eller derivatene, er beskrevet. DNA molekyler som koder for polypeptidene og fremgangsmåter for fremstilling av analogene er også beskrevet. Farmasøytiske formuleringer inneholdende en C5a analog blir anvendt terapeutisk for behandling av C5a-formidlede sykdommer og inflammatoriske tilstander i pattedyr, og profylaktisk for å forhindre eller redusere inflammasjon forårsaket av en heneldse som forårsaket inflammasjon eller forverrer en eksisterende inflammatorisk tilstand. Antistoffer spesifikke for C5a analoger, derivater derav og dimerer av anlogene og derivater som utviser vesentlig ingen kryss-reaktivitet med human C5a er også beskrevet. Antistoffene blir anvendt for å detektere eller kvantifisere sirkulerende C5a analog eller derivat og også modifisere, for eksempel nøytralisere aktiviteten til C5a reseptorantagonisten in vivo.Polypeptide analogs of human C5a which are C5a receptor antagonists exhibiting essentially no analphylatoxin or agonistic activity, and derivatives of the analogs, and dimeric forms of the analogs or derivatives, are described. DNA molecules encoding the polypeptides and methods for producing the analogs are also described. Pharmaceutical formulations containing a C5a analogue are used therapeutically to treat C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an incident causing inflammation or exacerbating an existing inflammatory state. Antibodies specific for C5a analogs, derivatives thereof and dimers of the analogs and derivatives exhibiting substantially no cross-reactivity with human C5a are also described. The antibodies are used to detect or quantify circulating C5a analog or derivative and also modify, for example, neutralize the activity of the C5a receptor antagonist in vivo.

NO962348A 1993-12-06 1996-06-05 C5a receptor antagonists without agonist activity NO962348L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16259193A 1993-12-06 1993-12-06
PCT/IB1994/000359 WO1995016033A1 (en) 1993-12-06 1994-11-16 C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY

Publications (2)

Publication Number Publication Date
NO962348D0 NO962348D0 (en) 1996-06-05
NO962348L true NO962348L (en) 1996-08-05

Family

ID=22586301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962348A NO962348L (en) 1993-12-06 1996-06-05 C5a receptor antagonists without agonist activity

Country Status (15)

Country Link
EP (1) EP0733107A1 (en)
JP (1) JPH09506258A (en)
CN (1) CN1142854A (en)
AU (1) AU698919B2 (en)
BR (1) BR9408265A (en)
CA (1) CA2176825A1 (en)
FI (1) FI962319A0 (en)
HU (1) HUT75990A (en)
IL (1) IL111792A0 (en)
MX (1) MXPA99008669A (en)
NO (1) NO962348L (en)
NZ (1) NZ274917A (en)
TW (1) TW429262B (en)
WO (1) WO1995016033A1 (en)
ZA (1) ZA949647B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
EP0832223A1 (en) * 1995-06-05 1998-04-01 Novartis AG C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY AND METHODS FOR PREPARATION
CN1087572C (en) * 1995-12-13 2002-07-10 北方电讯网络有限公司 Integrated cellular voice and digital packet data telecommunications system and method of operation of the system
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
TWI767415B (en) * 2020-11-18 2022-06-11 中國醫藥大學 Automatic blood analysis system and automatic blood analysis method
CN113150106B (en) * 2021-04-26 2022-08-16 华中农业大学 Antibacterial peptide derived from complement component C5a and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305615A1 (en) * 1987-09-03 1989-03-08 Immunetech Pharmaceuticals, Inc. Peptide antagonists for the C5a anaphylatoxin
ES2054667T3 (en) * 1986-04-28 1994-08-16 Cetus Oncology Corp MONOCLONAL ANTIBODIES AGAINST C5A AND DES-ARG74-C5A, THEIR PRODUCTION AND USE.

Also Published As

Publication number Publication date
CN1142854A (en) 1997-02-12
EP0733107A1 (en) 1996-09-25
HU9601538D0 (en) 1996-07-29
NO962348D0 (en) 1996-06-05
FI962319A7 (en) 1996-06-03
NZ274917A (en) 1998-03-25
AU698919B2 (en) 1998-11-12
IL111792A0 (en) 1995-01-24
HUT75990A (en) 1997-05-28
ZA949647B (en) 1995-06-06
MXPA99008669A (en) 2004-09-01
JPH09506258A (en) 1997-06-24
FI962319L (en) 1996-06-03
WO1995016033A1 (en) 1995-06-15
BR9408265A (en) 1996-12-10
FI962319A0 (en) 1996-06-03
CA2176825A1 (en) 1995-06-15
AU8002594A (en) 1995-06-27
TW429262B (en) 2001-04-11

Similar Documents

Publication Publication Date Title
Lenczowski et al. Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats
Kruse et al. Conversion of human interleukin‐4 into a high affinity antagonist by a single amino acid replacement.
Moser et al. Interleukin-8 antagonists generated by N-terminal modification.
Flanders et al. Localization and actions of transforming growth factor-β s in the embryonic nervous system
Sleeman et al. The ciliary neurotrophic factor and its receptor, CNTFRα
Al‐Humidan et al. Interleukin‐6 does not stimulate bone resorption in neonatal mouse calvariae
Gao et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells
Mummery et al. Characterization of the heparin-binding properties of IL-6
US6793919B2 (en) Methods for treating rheumatoid arthritis using IL-17 antagonists
Mantovani et al. Regulation of inhibitory pathways of the interleukin‐1 system
Jiang et al. Post-translational modification of a monocyte-specific chemoattractant synthesized by glioma, osteosarcoma, and vascular smooth muscle cells.
Rückert et al. MHC class I expression in murine skin: developmentally controlled and strikingly restricted intraepithelial expression during hair follicle morphogenesis and cycling, and response to cytokine treatment in vivo
WO2014007547A1 (en) Novel peptides and use thereof
DK203489A (en) ANTI-T-CELL RECEPTOR DETERMINANTS FOR DIAGNOSTICATION AND TREATMENT OF AUTOIMMUNE DISEASES
Cattaruzza et al. Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells
Rauner et al. Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities
US20210340208A1 (en) Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
DK169784D0 (en) PEPTIDES FOR PHARMACEUTICAL TREATMENT OF MAMMALS
JPH06329549A (en) Pharmaceutical comprising p40 subunit of interleukin 12
Zou et al. Structure-function analysis of the p35 subunit of mouse interleukin 12
Duncan et al. The local anti‐inflammatory action of dexamethasone in the rat carrageenin oedema model is reversed by an antiserum to lipocortin 1
Berglöf et al. IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells
NO962348L (en) C5a receptor antagonists without agonist activity
NO338682B1 (en) IL-18 binding protein (IL-18BP), a composition, method of preparation and use
Marikovsky et al. Appearance of leptin in wound fluid as a response to injury

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application